NASDAQ:VCYTVeracyte Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Veracyte Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $22.71 +1.35 (+6.32 %) (As of 04/8/2020 06:00 AM ET) Add Compare Share Today's Range$21.08Now: $22.71▼$23.1450-Day Range$16.13MA: $22.64▼$26.8552-Week Range$13.90Now: $22.71▼$31.18Volume619,852 shsAverage Volume511,536 shsMarket Capitalization$1.13 billionP/E RatioN/ADividend YieldN/ABeta0.93 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis. It sells its products through product specialists, account managers, and medical science specialists. Veracyte, Inc. has a strategic collaboration with Johnson & Johnson, LLC and Johnson & Johnson's Lung Cancer Initiative to advance diagnostics of a nasal swab test for early lung cancer detection; a research collaboration with Loxo Oncology for the development of therapies for patients with genetically defined cancers; and an agreement with Johnson & Johnson Services, Inc. for the development and commercialization of novel diagnostic tests to detect lung cancer. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingVeracyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.50, Veracyte has a potential upside of 43.1% from its current price of $22.71.Amount of Analyst CoverageVeracyte has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesVeracyte has received 365 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVeracyte has received 238 “underperform” votes. (Add your “underperform” vote.)Community SentimentVeracyte has received 60.53% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Veracyte and other stocks. Vote “Outperform” if you believe VCYT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VCYT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVeracyte does not currently pay a dividend.Dividend GrowthVeracyte does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Veracyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,858,440.00 in company stock.Percentage Held by InsidersOnly 8.30% of the stock of Veracyte is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Veracyte are expected to decrease by -42.37% in the coming year, from ($0.59) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veracyte is -84.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Veracyte is -84.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVeracyte has a P/B Ratio of 4.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.30 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VCYT Previous Symbol CUSIPN/A CIK1384101 Webhttp://www.veracyte.com/ Phone650-243-6300Debt Debt-to-Equity RatioN/A Current Ratio10.74 Quick Ratio10.35Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$120.37 million Price / Sales9.38 Cash FlowN/A Price / Cash FlowN/A Book Value$4.90 per share Price / Book4.63Profitability EPS (Most Recent Fiscal Year)($0.27) Net Income$-12,600,000.00 Net Margins-10.47% Return on Equity-6.47% Return on Assets-5.53%Miscellaneous Employees270 Outstanding Shares49,739,000Market Cap$1.13 billion Next Earnings Date5/5/2020 (Estimated) OptionableOptionable Receive VCYT News and Ratings via Email Sign-up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:VCYT Rates by TradingView Veracyte (NASDAQ:VCYT) Frequently Asked Questions How has Veracyte's stock been impacted by COVID-19 (Coronavirus)? Veracyte's stock was trading at $23.55 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VCYT stock has decreased by 3.6% and is now trading at $22.71. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Veracyte? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Veracyte. When is Veracyte's next earnings date? Veracyte is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Veracyte. How were Veracyte's earnings last quarter? Veracyte Inc (NASDAQ:VCYT) issued its quarterly earnings results on Tuesday, February, 25th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.06. The biotechnology company had revenue of $29.73 million for the quarter, compared to analysts' expectations of $29.35 million. Veracyte had a negative net margin of 10.47% and a negative return on equity of 6.47%. View Veracyte's earnings history. What guidance has Veracyte issued on next quarter's earnings? Veracyte issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $138-142 million, compared to the consensus revenue estimate of $136.41 million. What price target have analysts set for VCYT? 2 equities research analysts have issued 1 year target prices for Veracyte's shares. Their forecasts range from $30.00 to $35.00. On average, they expect Veracyte's stock price to reach $32.50 in the next twelve months. This suggests a possible upside of 43.1% from the stock's current price. View analysts' price targets for Veracyte. Has Veracyte been receiving favorable news coverage? News coverage about VCYT stock has trended very negative this week, InfoTrie reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Veracyte earned a news impact score of -3.3 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutVeracyte. Are investors shorting Veracyte? Veracyte saw a increase in short interest in March. As of March 13th, there was short interest totaling 4,692,800 shares, an increase of 21.6% from the February 27th total of 3,860,000 shares. Based on an average daily volume of 491,600 shares, the short-interest ratio is currently 9.5 days. Currently, 9.9% of the shares of the stock are sold short. View Veracyte's Current Options Chain. Who are some of Veracyte's key competitors? Some companies that are related to Veracyte include ELEKTA AB/ADR (EKTAY), Natera (NTRA), InVitae (NVTA), CareDx (CDNA), Castle Biosciences (CSTL), RadNet (RDNT), Centogene (CNTG), Personalis (PSNL), Fulgent Genetics (FLGT), DermTech (DMTK), Enzo Biochem (ENZ), Anpac Bio-Medical Science (ANPC), Celcuity (CELC), Biocept (BIOC) and Psychemedics (PMD). What other stocks do shareholders of Veracyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), Advanced Micro Devices (AMD), AbbVie (ABBV), BlackRock (BLK), Crispr Therapeutics (CRSP), Micron Technology (MU), Alibaba Group (BABA) and Amarin (AMRN). Who are Veracyte's key executives? Veracyte's management team includes the following people: Ms. Bonnie H. Anderson, Co-Founder, Chairman & CEO (Age 61)Mr. Christopher M. Hall, Pres & COO (Age 50)Mr. Keith S. Kennedy CFA, CPA, CFO & Sec. (Age 49)Dr. Giulia C. Kennedy Ph.D., Chief Scientific & Medical Officer (Age 60)Mr. Ashish Kheterpal, Chief Information Officer What is Veracyte's stock symbol? Veracyte trades on the NASDAQ under the ticker symbol "VCYT." How do I buy shares of Veracyte? Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Veracyte's stock price today? One share of VCYT stock can currently be purchased for approximately $22.71. How big of a company is Veracyte? Veracyte has a market capitalization of $1.13 billion and generates $120.37 million in revenue each year. The biotechnology company earns $-12,600,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Veracyte employs 270 workers across the globe. View additional information about Veracyte. What is Veracyte's official website? The official website for Veracyte is http://www.veracyte.com/. How can I contact Veracyte? Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected] This page was last updated on 4/8/2020 by MarketBeat.com StaffFeatured Article: Gross Domestic Product (GDP)
